Recently, phase-3 trial ECHELON-2 (NCT01777152) concerning the use of brentuximab vedotin in previously untreated CD30 + patients with PTCL has been initiated [69]. This evidence concerns the gene TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma.